

I.B. AMENDMENTS TO THE CLAIMS

Cancel claims 16-19 without prejudice to renewal.

Please enter the amendments to claims 4, 5, and 7-15, as shown below.

Please enter new claims 28-32, as shown below.

1. (Original) A method of treating hypertension, comprising administering to a patient in need thereof a pharmaceutical formulation comprising pharmaceutically active relaxin in an amount effective to reduce hypertension.

2. (Original) The method according to claim 1, wherein the hypertension is renal hypertension.

3. (Original) The method according to claim 1, wherein the hypertension is pulmonary hypertension.

4. (Currently Amended) The method of claim 1, wherein the relaxin is administered to the patient in an amount in a range of about from 0.1 to 500 µg/kg of patient body weight.

5. (Currently Amended) The method of claim 1, wherein the formulation is administered daily over a period of time sufficient to obtain a therapeutic effect in the patient.

6. (Original) The method of claim 1, wherein the formulation is an injectable formulation.

7. (Currently Amended) The method of claim 1, wherein relaxin is administered to the patient at a predetermined rate so as to maintain a serum concentration of relaxin of from about 0.5 to 50 ng/ml and continuing the administration over a period of time sufficient to obtain a therapeutic effect in the patient.

8. (Currently Amended) A method of treating hypertension, comprising administering an injectable formulation comprising pharmaceutically active recombinant human relaxin to a patient in an amount in a range of about from 0.1 to 500 µg/kg of patient body weight, and continuing the

administration over a period of time sufficient to obtain a therapeutic effect in the patient.

9. (Currently Amended) A method of increasing vasodilation, comprising administering to a patient in need thereof a pharmaceutical formulation comprising pharmaceutically active recombinant human relaxin in an amount effective to increase vasodilation.

10. (Currently Amended) The method of claim 9, wherein the relaxin is administered to the patient in an amount in a range of about from 0.1 to 500 $\mu\text{g}/\text{kg}$ of patient body weight.

11. (Currently Amended) The method of claim 9, wherein the formulation is an injectable formulation, wherein the pharmaceutically active recombinant human relaxin is administered to a patient in an amount in a range of about from 0.1 to 500 $\mu\text{g}/\text{kg}$ of patient body weight, and wherein the administration is continued over a period of time sufficient to obtain a therapeutic effect in the patient.

12. (Currently Amended) A method of increasing renal function, comprising administering to a patient in need thereof a pharmaceutical formulation comprising pharmaceutically active relaxin in an amount effective to increase a parameter factor associated with renal function.

13. (Currently Amended) The method of claim 12, wherein the parameter factor associated with renal function is glomerular filtration rate.

14. (Currently Amended) The method of claim 12, wherein the relaxin is administered to the patient in an amount in a range of about from 0.1 to 500 $\mu\text{g}/\text{kg}$ of patient body weight.

15. (Currently Amended) The method of claim 12, wherein the formulation is an injectable formulation, wherein the pharmaceutically active recombinant human relaxin is administered to a patient in an amount in a range of about from 0.1 to 500 $\mu\text{g}/\text{kg}$ of patient body weight, and wherein the administration is continued over a period of time sufficient to obtain a therapeutic effect in the patient.

16-19. (Canceled)

N.R.

20-27. (Withdrawn)

A7

-- 28. (New) A method of treating pulmonary hypertension, comprising administering to a patient in need thereof a pharmaceutical formulation comprising pharmaceutically active relaxin in an amount effective to reduce pulmonary hypertension.

29. (New) The method of claim 28, wherein the relaxin is administered to the patient in an amount in a range of from 0.1 to 500 $\mu\text{g}/\text{kg}$ of patient body weight.

30. (New) The method of claim 28, wherein the formulation is administered daily over a period of time to obtain a therapeutic effect in the patient.

31. (New) The method of claim 28, wherein the formulation is an injectable formulation.

32. (New) The method of claim 28, wherein relaxin is administered to the patient at a predetermined rate so as to maintain a serum concentration of relaxin of from 0.5 to 50 ng/ml and continuing the administration over a period of time sufficient to obtain a therapeutic effect in the patient.